Skip to main content

Buprenorphine Treatment in Community Settings

Sponsored By:

Dr. Galanter will describe our published outcome study by program type based upon the intensity of counseling and recovery oriented services. Dr. Femino will discuss the clinical aspects and implications for treatment planning from a neurobiological perspective. A discussion of past research on the relative benefit of adding counseling to medication will be reviewed with emphasis on the limitations of controlled trials compared to clinical care.

Participants will review strategies of how to expand counseling beyond medication management into the psychosocial and spiritual aspects of recovery. Review of “recovery dose equivalency” as a targeted method in early recovery to stabilize neurobiological survival circuitry and in later recovery to target counseling to executive functioning necessary for sustained recovery.

Discussion will focus upon the real world implications of incorporating counseling when patients do not believe that counseling is necessary and current clinical guidelines only require “the capacity to refer.” The treatment implications and development of clinical protocols using more comprehensive addiction assessment instruments and electronic medical databases combined with brain imaging techniques, genetic and pharmacokinetic testing, and use of neuropsychological testing will be discussed as a novel method of individualization of care.

Upon completion of this webinar, attendees will:

  • Understand limitations of controlled trials on the role of counseling in MAT
  • Develop strategies to expand counseling beyond medication management
  • Review the importance of patient and program characteristics on drug testing outcome data
Back to Top